(G.N.S) Dt. 29 London Novavax said the trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for regulatory review in Britain, the European Union and other countries. Some 27% of people in the trial are over 65. Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as
This content is restricted to site members. If you are an existing user, please log in. New users may register below.